Table 2.
Reasons for changing to another biologic or discontinuation of therapy
| CT-P13 (N = 105) | Reference infliximab (N = 92) | |||||
|---|---|---|---|---|---|---|
| Overall (N = 105) | First line (n = 82) | Subsequent line (n = 23) | Overall (N = 92) | First line (n = 62) | Subsequent line (n = 30) | |
| Patients changing biologic or discontinuing therapy, n | 39 | 30 | 9 | 41 | 29 | 12 |
| Patients changing biologic, n | 21 | 15 | 6 | 14 | 10 | 4 |
| Inefficacy | 13 | 10 | 3 | 9 | 6 | 3 |
| AE | 8 | 5 | 3 | 5 | 4 | 1 |
| Patients discontinuing therapy, n | 18 | 15 | 3 | 27 | 19 | 8 |
| Clinical remission | 4 | 4 | 3 | 2 | 1 | |
| Inefficacy | 2 | 2 | 1 | 1 | ||
| AE | 5 | 4 | 1 | 12 | 9 | 3 |
| Other reasons | 7 | 5 | 2 | 11 | 7 | 4 |
| Loss to follow-up | 2 | 2 | 2 | 1 | 1 | |
| Optionally stopped | 1 | 1 | 1 | 1 | ||
| Patient’s will | 2 | 1 | 1 | 5 | 3 | 2 |
| Plan for pregnancy | 1 | 1 | 1 | 1 | ||
| Insurance costs | 2 | 2 | ||||
| Unknown | 1 | 1 | ||||
AE adverse event